Last reviewed · How we verify
NCT03486821
Ultra-hypofractionated Radiation in Prostate Cancer
NA trial testing Hypofractionated Radiation in Early Stage Prostate Cancer in 13 participants. Participants enrolled and being followed up; not accepting new ones.
1 March 2025
Quick facts
| Lead sponsor | University of Kansas Medical Center |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 13 |
| Start date | 22 March 2018 |
| Primary completion | 1 March 2025 |
| Estimated completion | 1 March 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Hypofractionated Radiation
Conditions studied
- Early Stage Prostate Cancer — all drugs for Early Stage Prostate Cancer →
Sponsor
University of Kansas Medical Center
Who can join
18 and older, male only, with Early Stage Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to demonstrate that ultra-hypofractionation of prostate cancer does not increase urinary toxicity as defined by the EPIC-26 GU domain patient reported outcome.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A Pilot Trial of Two-Fraction Stereotactic Body Radiation Therapy for Localized Prostate Cancer.
Shen X, Chen M, Cao Y, Schroeder A, et al · · 2025 · PMID 41631234 · DOI 10.7759/cureus.100519
Verify or expand the search:
- PubMed search for NCT03486821
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Hypofractionated Radiation
Trials testing the same drug.
- NCT04683653 — Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer · Phase 1, PHASE2 · recruiting
Other University of Kansas Medical Center trials
Trials by the same sponsor.
- NCT06636214 — Adapting Changing Talk: Online (CHATO) to CHATO-Inclusive · NA · not yet recruiting
- NCT07528963 — KanSurvive 2.0: Testing Enhanced Models of Cancer Survivorship Care for Rural Cancer Survivors in Primary Care Practice · NA · enrolling by invitation
- NCT07463755 — Low-Fidelity Driving Simulator Training in Parkinson's Disease. · NA · not yet recruiting
- NCT07420621 — Preliminary Effectiveness of Enhanced Text Message + Incentives · NA · recruiting
- NCT07491510 — Improving Prenatal Care to Reduce Early Onset Preeclampsia in Low-Income · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03486821 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Kansas Medical Center
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03486821.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing